I can't say empircally with any degree of exactitude what they will say obviously, but the primary outcome according to Resverlogix's website is:  

The primary endpoint in BETonMACE – the outcome we are measuring that will deem the trial a success – is the time to first occurrence of Major Adverse Cardiac Events (MACE).

In a PR from April of this year its worded thusly: 

The primary endpoint of the BETonMACE trial is designed to show a relative risk reduction of narrowly defined MACE for patients who remain on a high-dose statin therapy and top standard of care.

While it doesn't say it in either example, I believe it entails showing a statiscally significant improvement in the time to first occurence of MACE...whether that's 15%, 20%, 35% or whatever.

So if the trial is a success I imagine it would be announced in a manner something along the lines of:

We are pleased to announce that the results from the BETonMACE trial show that Apabetalone achieved the primary endpoint of achieving a statiscally signficant relative risk reduction of narrowly defined three point MACE in high risk diabetic patients with low HDL cholesterol who had suffered a major adverse cardiac event within the last 90 days prior to first dosing.  Further details will be announced at....blah blah blah.

I think BDZ is the go to guy when it comes to the blah blah blah part...he has a great handle on all the upcoming presentations and conferences that could be possibilities.